Cellular Biomedicine Group, Inc. (CBMG)
(Delayed Data from NSDQ)
$17.16 USD
+0.43 (2.57%)
Updated May 3, 2019 04:00 PM ET
After-Market: $16.97 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$17.16 USD
+0.43 (2.57%)
Updated May 3, 2019 04:00 PM ET
After-Market: $16.97 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Cellular Biomedicine Group (CBMG) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Cellular Biomedicine (CBMG) delivered earnings and revenue surprises of -2.27% and -48.00%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Cellular Biomedicine Group (CBMG) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cellular Biomedicine (CBMG) delivered earnings and revenue surprises of -7.69% and 40.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Cellular Biomedicine Group (CBMG) Q3 Earnings Expected to Decline
by Zacks Equity Research
Cellular Biomedicine (CBMG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cellular Biomedicine Group (CBMG) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cellular Biomedicine (CBMG) delivered earnings and revenue surprises of -1.92% and 50.98%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
GE Collaborates with CBMG to Enhance Healthcare Portfolio
by Zacks Equity Research
General Electric Company (GE) recently collaborated with Cellular Biomedicine Group Inc. (CBMG) to co-develop certain high-quality industrial control processes in Chimeric Antigen Receptor T-cell (CAR-T) and stem cell manufacturing.